Phlebitis and thrombophlebitis of unspecified site
Methodology & AI Transparency ⓘ
Phlebitis and thrombophlebitis of unspecified site Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as I80.9, Phlebitis and thrombophlebitis of unspecified site falls under Blood Pressure management, where 24-hour ambulatory blood in Phlebitis and thrombophlebitis of unspecified site (I80.9: pressure monitoring) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Phlebitis and thrombophlebitis of unspecified site uses ICD-10 I80.9 across Blood Pressure specialty care.
- 3 Typical cash cost range: Primary evaluation for Phlebitis and thrombophlebitis of unspecified site incorporates 24-hour ambulatory blood in Phlebitis and thrombophlebitis of unspecified site (I80.9: pressure monitoring) and symptom diary review.
- 4 Top reported side effects / signs: Key Blood Pressure biomarkers for Phlebitis and thrombophlebitis of unspecified site (I80.9): Urine Albumin-to-Creatinine Ratio [Phlebitis and thrombophlebitis of unspecified site I80.9] & Home Seated Blood in Phlebitis and thrombophlebitis of unspecified site (I80.9: Pressure) (< 120/75 mmHg (I80.9)).
Ask our AI Specialists anything about Phlebitis and thrombophlebitis of unspecified site
What Is Phlebitis and thrombophlebitis of unspecified site?
Designated in federal medical registries as I80.9, Phlebitis and thrombophlebitis of unspecified site falls under Blood Pressure management, where 24-hour ambulatory blood in Phlebitis and thrombophlebitis of unspecified site (I80.9: pressure monitoring) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Phlebitis and thrombophlebitis of unspecified site (I80.9, Blood Pressure) reflects arterial smooth-muscle hypertrophy [Phlebitis and thrombophlebitis of unspecified site I80.9]. longitudinal control is benchmarked via Urine Albumin-to-Creatinine Ratio [Phlebitis and thrombophlebitis of unspecified site I80.9].
Common Symptoms & Clinical Signs
- • Presentation of Phlebitis and thrombophlebitis of unspecified site (I80.9): localized extremity swelling, in Phlebitis and thrombophlebitis of unspecified site (I80.9: warmth, or venous)
- • Secondary Phlebitis and thrombophlebitis of unspecified site clinical sign: cold distal extremities in Phlebitis and thrombophlebitis of unspecified site (I80.9: or diminished peripheral)
- • Symptom flares in Phlebitis and thrombophlebitis of unspecified site correlating with Urine Albumin-to-Creatinine Ratio [Phlebitis and thrombophlebitis of unspecified site I80.9] deviation outside < 15 mg/g (I80.9)
- • Functional blood pressure impact requiring 24-hour ambulatory blood in Phlebitis and thrombophlebitis of unspecified site (I80.9: pressure monitoring) evaluation (I80.9)
Phlebitis and thrombophlebitis of unspecified site Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I80.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Phlebitis and thrombophlebitis of unspecified site I80.9] | < 15 mg/g (I80.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Phlebitis and thrombophlebitis of unspecified site (I80.9: Pressure) | < 120/75 mmHg (I80.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Phlebitis and thrombophlebitis of unspecified site I80.9] | 1.00 – 1.30 (I80.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Phlebitis and thrombophlebitis of unspecified site
Treatment selection for Phlebitis and thrombophlebitis of unspecified site depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Phlebitis and thrombophlebitis of unspecified site)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of single-pill combination in uncontrolled essential high blood: What a 273-Participant Study Found Based on Ranking Plot of the Network, we can conclude that single-pill combination blood-pressure-lowering drugs are superior to single-drug treatment, and ARB/CCB combination has better advantages than other SPC in terms of... Clinical cardiology • 2023-08-15 • Meta-Analysis | N = 273 | 91/100 | PMID 37432701 ↗ |
| Can This Approach Help? Inside the Latest Research on Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year In this post hoc analysis, tirzepatide treatment was associated with a significant reduction in predicted 10-year CVD risk versus placebo, which was associated with an increase in predicted risk, supporting the potential role... Current medical research and opinion • 2026-04-15 • Phase III Randomized Trial | N = 64 | 88/100 | PMID 42287159 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of suvorexant on nighttime blood pressure in hypertensive patients with Clinic, 24-hour, daytime and morning SBP (ambulatory blood pressure monitoring) also decreased slightly and similarly from baseline in both groups. Journal of clinical hypertension (Greenwich, Conn.) • 2019-07-15 • Randomized Controlled Trial | N = 82 | 88/100 | PMID 30874378 ↗ |
| Can This Approach Help? Inside the Latest Research on Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential L50/H12.5/A5 was well tolerated. Hypertension research : official journal of the Japanese Society of Hypertension • 2015-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 25716649 ↗ |
| New Insights on Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and: What a 700-Participant Study Found Of the 700 included patients, 403 (57.6%) were female, and the mean (SD) age was 56 (11) years. JAMA cardiology • 2020-11-01 • Randomized Controlled Trial | N = 700 | 87/100 | PMID 32717045 ↗ |
Phlebitis and thrombophlebitis of unspecified site Patient Community & “People Like Me” Threads
Filter Phlebitis and thrombophlebitis of unspecified site community threads and patient logs by age, biological sex, dosage, and treatment duration.